The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CST Outcomes

Article-CST Outcomes

follows-up on recent stories

In our January/February 2007 issue, we covered the latest news on promising new evidence that could address the well-known limitation of fat transplantation used as a filler in plastic and reconstructive surgery. (See “Stemming Time’s Tides.”)

Early evidence suggested that neovascularization can be engendered in a fat transplant by supplementing the implanted tissue with autologous adipose-derived stem cells (ADCs). As reported on consumer cosmetic surgery site, a new device on the market, the Celution System, used to extract ADCs, is now being used in a new and innovative procedure called “Celution,” which has just been approved in the European Union. The technique will first focus on breast reconstruction for women who have undergone a partial mastectomy or lumpectomy. However, breast augmentation through the Celution technique may be a possibility in the future for women looking for minimally invasive, virtually scarless breast augmentation.

The system sterilely disaggregates adipose tissue using a temperature and enzyme-driven process. Within an hour, the surgeon has a syringe containing concentrated stem cells that are injected into the patient’s breast tissue. Within six months post procedure, breasts may enlarge by up to two cup sizes.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.